Annovis Bio (ANVS) Net Equity Issued and Repurchased (2020 - 2024)
Annovis Bio (ANVS) posted Net Equity Issued and Repurchased of $6.2 million for Q4 2024, up 42.37% sequentially from $4.4 million in Q3 2024, and down 25.43% YoY from $8.3 million in Q1 2024.
Annovis Bio (ANVS) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Annovis Bio has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $6.2 million in Q4 2024.
- Quarterly Net Equity Issued and Repurchased fell 25.43% year-over-year to $6.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18.6 million (up 124.89% YoY) and the FY2024 annual result came in at $18.7 million, up 10.55% from the prior year.
- Net Equity Issued and Repurchased grew to $6.2 million in Q4 2024 per ANVS's latest filing, from $4.4 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $12.1 million in Q1 2020 and troughed at -$50000.0 in Q2 2020.
- A 4-year average of $4.9 million and a median of $4.3 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 25.43% in 2024, down 25.43% in 2024.
- Over 4 years, Net Equity Issued and Repurchased stood at -$50000.0 in 2020, then surged by 49.09% to -$25456.0 in 2021, then soared by 32763.24% to $8.3 million in 2023, then slipped by 25.43% to $6.2 million in 2024.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $6.2 million, $4.4 million, and $4.2 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.20 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Sep 30, 2021 | -25,456.00 |
| Sep 30, 2021 | -25,456.00 |
| Jun 30, 2020 | -50,000.00 |
| Jun 30, 2020 | -50,000.00 |
| Mar 31, 2020 | 12.08 Mn |
| Mar 31, 2020 | 12.08 Mn |